• Sun. Dec 3rd, 2023

Latest Developments in Health Care Market Negotiations


Nov 21, 2023

Jefferies analysts have published their latest Market Talks covering the Health Care sector, which was exclusively published on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. According to the note from Jefferies analysts, Bayer is facing challenges on multiple fronts that are hastening the need to explore strategic options. The halt of a late-stage clinical trial of experimental cardiovascular drug asundexian pushes financial risk to the edge, while share-price falls increase sensitivity to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. This suggests that the German pharmaceutical-and-agricultural group might need to sell assets and scrap dividends to buy time. However, this may not be enough to enable large-scale investments needed in its pharma business, Jefferies says. As a result, Jefferies has cut its recommendation on the stock from buy to hold. Despite this, shares trade 0.3% higher following Monday’s heavy losses. (adria.calatayud@dowjones.com) Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Leave a Reply